Change in arm mobility after self-application of yoga or cupping following unilateral breast cancer surgery

Change in arm mobility after self-application of yoga or cupping following unilateral breast cancer surgery - MOYOCU

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00038840

Enrollment

Registered

2026-03-24

Start date

2024-09-12

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Change in arm mobility after self-application of yoga or cupping following unilateral breast cancer surgery C50

Interventions

Group 1: Cupping: 5 interventions (20 minutes each) within 1 week with a maximum of 1 day break over 3 weeks (15 interventions in total) Group 2: Yoga: 5 interventions (20 minutes each) within 1 week

Eligibility

Sex/Gender

Female

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: • Cisgender women with a primary diagnosis of unilateral breast cancer (including DCIS) • EGOG status 0 to 1 (determined by the study director, if necessary) • Women who are proficient in German • Signed declaration of consent • Mental and intellectual capacity to perform the exercises

Exclusion criteria

Exclusion criteria: • Cisgender men • Transgender individuals • Pregnant women • Women with recurrent breast cancer and women with an ECOG status of 2 or higher • Use of blood thinners

Design outcomes

Primary

Measure	Time frame
Primary objective: To assess the feasibility of a follow-up study based on patient compliance Primary endpoint: • Patient compliance (adherence to therapy/self-treatment), measured by: • Recruitment rate, • Participation rate/dropout rate, • Completion rate Duration of study-related measures: Initial measurement after diagnosis, second measurement before surgery, 3-week self-treatment period starting 4-7 days after surgery, third measurement 1-7 days after the end of the self-treatment period	—

Measure

Time frame

Primary objective: To assess the feasibility of a follow-up study based on patient compliance Primary endpoint: • Patient compliance (adherence to therapy/self-treatment), measured by: • Recruitment rate, • Participation rate/dropout rate, • Completion rate Duration of study-related measures: Initial measurement after diagnosis, second measurement before surgery, 3-week self-treatment period starting 4-7 days after surgery, third measurement 1-7 days after the end of the self-treatment period

—

Secondary

Measure	Time frame
Secondary objectives: Effect of active movement therapy in the form of yoga exercises and cupping with a silicone cup on arm mobility after unilateral breast surgery, scar mobility, and the range of motion of the arms. Secondary endpoints: • Arm mobility (range of motion (ROM)), measured with a goniometer, • Tissue stiffness, measured with IndentoPRO • Tissue mobility in the scar area, measured with an adheremeter • Ability to perform certain activities, measured using the DASH questionnaire Tertiary objectives: Effect of active movement therapy on the subjective well-being and psychological resilience of the test subjects. Tertiary endpoints: • Emotional resilience/subjective well-being, measured using HRV (heart rate variability) and the DASH questionnaire	—

Measure

Time frame

Secondary objectives: Effect of active movement therapy in the form of yoga exercises and cupping with a silicone cup on arm mobility after unilateral breast surgery, scar mobility, and the range of motion of the arms. Secondary endpoints: • Arm mobility (range of motion (ROM)), measured with a goniometer, • Tissue stiffness, measured with IndentoPRO • Tissue mobility in the scar area, measured with an adheremeter • Ability to perform certain activities, measured using the DASH questionnaire Tertiary objectives: Effect of active movement therapy on the subjective well-being and psychological resilience of the test subjects. Tertiary endpoints: • Emotional resilience/subjective well-being, measured using HRV (heart rate variability) and the DASH questionnaire

—

Countries

Germany

Contacts

Public ContactMiriam Wessels

privat

Miriam@MiriamWessels.de+49 177 514 9363

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026